CHCWM – Cancer & Hematology Centers of West Michigan

C-1400-01 (AGEN1777) (Agenus, Inc.)

C-1400-01 (AGEN1777) (Agenus, Inc.)

Description:  A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors

Mechanism of Action: bispecific antibody targeting TIGIT and CD96 (to enhance T and NK cell activation)

Target Population:  All solid tumors.  To be given as single agent or in combination with Balstilimab

Study Design:  Study drug is administered IV every 3 weeks.